Edesa Biotech Shares Outstanding History (EDSA)
Edesa Biotech reported 7.1M shares outstanding at the end of fiscal 2025.
View full Edesa Biotech company overviewEdesa Biotech annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | 7.1M | 3.9M | +119.92% |
| 2024 | 2024-09-30 | 3.2M | 171,916 | +5.59% |
| 2023 | 2023-09-30 | 3.1M | 695,193 | +29.21% |
| 2022 | 2022-09-30 | 2.4M | −10.9M | −82.10% |
| 2021 | 2021-09-30 | 13.3M | 3.7M | +38.28% |
| 2020 | 2020-09-30 | 9.6M | 2.1M | +28.13% |
| 2019 | 2019-09-30 | 7.5M | 2.2M | +40.78% |
| 2018 | 2018-09-30 | 5.3M | 3.8M | +254.70% |
| 2017 | 2017-09-30 | 1.5M | −8.6M | −85.17% |
| 2016 | 2016-09-30 | 10.1M | 2.2M | +26.95% |
| 2015 | 2015-09-30 | 8.0M | 157,873 | +2.02% |
| 2014 | 2014-08-31 | 7.8M | −50.1M | −86.49% |
| 2013 | 2013-08-31 | 57.9M | — | — |
Edesa Biotech quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | 9.6M | 2.6M | +37.17% |
| Q2 2026 | 2026-03-31 | 8.9M | 1.9M | +26.53% |
| Q1 2026 | 2025-12-31 | 8.3M | 4.9M | +140.33% |
| Q4 2025 | 2025-09-30 | 7.1M | 3.9M | +119.92% |
| Q3 2025 | 2025-06-30 | 7.0M | 3.8M | +116.26% |
| Q2 2025 | 2025-03-31 | 7.0M | 3.8M | +118.37% |
| Q1 2025 | 2024-12-31 | 3.5M | 302,936 | +9.57% |
| Q4 2024 | 2024-09-30 | 3.2M | 171,916 | +5.59% |
| Q3 2024 | 2024-06-30 | 3.2M | −17.6M | −84.44% |
| Q2 2024 | 2024-03-31 | 3.2M | −16.8M | −83.97% |
| Q1 2024 | 2023-12-31 | 3.2M | −16.2M | −83.65% |
| Q4 2023 | 2023-09-30 | 3.1M | −13.6M | −81.54% |
| Q3 2023 | 2023-06-30 | 20.9M | 5.4M | +34.95% |
| Q2 2023 | 2023-03-31 | 20.1M | 4.6M | +29.73% |
| Q1 2023 | 2022-12-31 | 19.4M | 5.8M | +43.16% |
| Q4 2022 | 2022-09-30 | 16.7M | 3.4M | +25.32% |
| Q3 2022 | 2022-06-30 | 15.5M | 2.2M | +16.65% |
| Q2 2022 | 2022-03-31 | 15.5M | 2.2M | +16.73% |
| Q1 2022 | 2021-12-31 | 13.5M | 3.0M | +28.47% |
| Q4 2021 | 2021-09-30 | 13.3M | 3.7M | +38.28% |
| Q3 2021 | 2021-06-30 | 13.3M | 4.4M | +49.58% |
| Q2 2021 | 2021-03-31 | 13.2M | 4.4M | +49.52% |
| Q1 2021 | 2020-12-31 | 10.5M | 3.0M | +40.22% |
| Q4 2020 | 2020-09-30 | 9.6M | 2.1M | +28.13% |
| Q3 2020 | 2020-06-30 | 8.9M | 1.4M | +18.09% |
| Q2 2020 | 2020-03-31 | 8.9M | 3.5M | +66.19% |
| Q1 2020 | 2019-12-31 | 7.5M | 2.2M | +40.78% |
| Q4 2019 | 2019-09-30 | 7.5M | 2.2M | +40.78% |
| Q3 2019 | 2019-06-30 | 7.5M | 2.2M | +40.78% |
| Q2 2019 | 2019-03-31 | 5.3M | 3.8M | +254.70% |
| Q1 2019 | 2018-12-31 | 5.3M | −5.2M | −49.33% |
| Q4 2018 | 2018-09-30 | 5.3M | −5.2M | −49.33% |
| Q3 2018 | 2018-06-30 | 5.3M | −5.2M | −49.33% |
| Q2 2018 | 2018-03-31 | 1.5M | −8.6M | −85.17% |
| Q1 2018 | 2017-12-31 | 10.5M | 383,838 | +3.79% |
| Q4 2017 | 2017-09-30 | 10.5M | 383,838 | +3.79% |
| Q3 2017 | 2017-06-30 | 10.5M | 2.1M | +24.52% |
| Q2 2017 | 2017-03-31 | 10.1M | 1.7M | +19.97% |
| Q1 2017 | 2016-12-31 | 10.1M | 1.7M | +19.97% |
| Q4 2016 | 2016-09-30 | 10.1M | 2.2M | +26.95% |
| Q3 2016 | 2016-06-30 | 8.4M | −71.1M | −89.38% |
| Q2 2016 | 2016-03-31 | 8.4M | −71.1M | −89.38% |
| Q1 2016 | 2015-12-31 | 8.4M | −71.1M | −89.38% |
| Q4 2015 | 2015-09-30 | 8.0M | −71.4M | −89.95% |
| Q3 2015 | 2015-06-30 | 79.5M | 1.3M | +1.63% |
| Q2 2015 | 2015-03-31 | 79.5M | 21.6M | +37.28% |
| Q1 2015 | 2014-12-31 | 79.5M | — | — |
| As of Sep 30, 2014 | 2014-09-30 | 79.4M | — | — |
| Q4 2014 | 2014-08-31 | 78.3M | — | — |
| Q4 2013 | 2013-08-31 | 57.9M | — | — |
Edesa Biotech shares outstanding trends
Over the last five reported fiscal years, Edesa Biotech's shares outstanding moved from 9.6M to 7.1M, a change of −2.5M. The latest reported quarter, Q3 2026, shows 9.6M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Edesa Biotech filings at SEC.gov ↗